299 related articles for article (PubMed ID: 31358010)
1. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
2. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
3. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
4. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
5. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
6. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
[TBL] [Abstract][Full Text] [Related]
7. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
[TBL] [Abstract][Full Text] [Related]
8. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
Semczuk A; Miturski R; Skomra D; Jakowicki JA
Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
[TBL] [Abstract][Full Text] [Related]
9. Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines.
Kitahara K; Yasui W; Yokozaki H; Semba S; Hamamoto T; Hisatsugu T; Tahara E
J Exp Ther Oncol; 1996 Jan; 1(1):7-12. PubMed ID: 9414383
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
[TBL] [Abstract][Full Text] [Related]
11. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report.
Tang B; Sheng X; Kong Y; Chi Z; Si L; Cui C; Yan X; Mao L; Lian B; Li S; Wang X; Dai J; Bai X; Zhou L; Guo J
Chin Clin Oncol; 2018 Dec; 7(6):62. PubMed ID: 30180747
[TBL] [Abstract][Full Text] [Related]
14. Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.
Ismail A; Bandla S; Reveiller M; Toia L; Zhou Z; Gooding WE; Kalatskaya I; Stein L; D'Souza M; Litle VR; Peters JH; Pennathur A; Luketich JD; Godfrey TE
Clin Cancer Res; 2011 Jul; 17(13):4513-22. PubMed ID: 21593195
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
17. P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.
Li P; Zhang X; Gu L; Zhou J; Deng D
PLoS One; 2019; 14(10):e0223084. PubMed ID: 31652270
[TBL] [Abstract][Full Text] [Related]
18. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
[TBL] [Abstract][Full Text] [Related]
19. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
